Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- New York-Presbyterian Westchester Hospital — Bronxville, New York
- New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Hematology Oncology Associates of CNY at Camillus — Camillus, New York
- Hematology Oncology Associates of Central New York-East Syracuse — East Syracuse, New York
- Northwell Health Cancer Institute at Huntington — Greenlawn, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in New York: - New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — East White Plains, New York
- The New York Hospital Medical Center of Queens — Flushing, New York
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in New York: - New York Oncology Hematology (NYOH) — Amsterdam, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Hematology Oncology Associates of Central New York, PC — East Syracuse, New York
- Northwell Health — Lake Success, New York
- Laura and Isaac Perlmutter Cancer Canter — New York, New York
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in New York: - Research Site — Bay Shore, New York
- Research Site — East Syracuse, New York
- Research Site — Greenlawn, New York
- Research Site — New Hyde Park, New York
- Research Site — New York, New York
Phase 3 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…
Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in New York: - Queens Cancer Center of Queens Hospital — Jamaica, New York
- Optum Health — Lake Success, New York
- Mount Sinai School of Medicine — New York, New York
Phase 3 Recruiting Industry
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced…
Sponsor: AstraZeneca
NCT ID: NCT04862663
Sites in New York: - Research Site — Brooklyn, New York
- Research Site — Mineola, New York
- Research Site — New York, New York
- Research Site — New York, New York
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine…
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT06016738
Sites in New York: - Clinical Trial Site — New York, New York
- Clinical Trial Site — Port Jefferson Station, New York
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in New York: - New York Oncology Hematology — Albany, New York
- New York-Presbyterian - Columbia University Irving Medical Center — New York, New York
- Stony Brook University Cancer Center — Stony Brook, New York
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in New York: - Research Site — New York, New York
- Research Site — Syracuse, New York
Phase 3 Recruiting Industry
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participant…
Sponsor: BioNTech SE
NCT ID: NCT07173751
Sites in New York: - Rochester General Hospital Lipson Cancer Institute — Rochester, New York
- Stony Brook University Medical Center — Stony Brook, New York
- Montefiore Medical Center — The Bronx, New York
Phase 3 Recruiting Academic/Other
The purpose of this study is to compare using FDA-approved bupivacaine (a numbing medicine), along with the usual medications for post-operative pain control to using the usual medications for postoperative pain control alone. The addition…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03351348
Sites in New York: - Memorial Sloan Kettering Commack (Consent and follow-up only) — Commack, New York
- Memorial Sloan Kettering Westchester (Consent and follow-up only) — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau (Consent and follow-up only) — Uniondale, New York
Phase 3 Recruiting Industry
A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
Sponsor: AstraZeneca
NCT ID: NCT07205822
Sites in New York: - Research Site — New York, New York
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the reco…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05563220
Sites in New York: - NYU Langone Health — New York, New York
- New York Cancer and Blood Specialists — Port Jefferson Station, New York
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in New York: - Northwell Health — Lake Success, New York
- Laura & Isaac Perlmutter Cancer Center at NYC Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- North Shore Hematology Oncology Associate P.C. DBA New York Cancer and Blood Specialists — Shirley, New York
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in New York: - University of Rochester Medical Center — Rochester, New York
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in New York: - Columbia University — New York, New York
- Memorial Sloan Kettering — New York, New York
Phase 2 Recruiting Industry
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Sponsor: Criterium, Inc.
NCT ID: NCT04567420
Sites in New York: - Icahn School of Medicine at Mount Sinai — New York, New York
- Stony Brook University Cancer Center — Stony Brook, New York
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05315700
Sites in New York: - NYU Langone Health Perlmutter Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT06998407
Sites in New York: - Avenzo Therapeutics Recruiting Site — New York, New York
Phase 2 Recruiting Academic/Other
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03808337
Sites in New York: - Memorial Sloan Kettering Cancer Center @ Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: * Cohort 1: Patients with ER+ / HER2- b…
Sponsor: Aminex Therapeutics, Inc.
NCT ID: NCT07287917
Sites in New York: - START Cancer Research New York-Long Island — Lake Success, New York
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also l…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05570253
Sites in New York: - Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) — Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) — Uniondale, New York